For the NSCLC analysis, although the lines do cross, the slopes of the lines are not significantly different for the anti-PD-1/PD-L1 agents vs chemotherapy and indicate no distinct relationship particular to NSCLC patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.